Cancer Therapy & Research Center
7979 Wurzbach Rd., San Antonio, TX 78229 (210) 450-1000
Toll free: 1-800-340-CTRC (2872)
Toll free: 1-800-340-CTRC (2872)
In this Phase III study patients with recurrent or metastatic Head and Neck Cancer will be randomized to receive standard platinum-based chemotherapy with or without Bevacizumab. Standard regimen can be Docetaxel+Cisplatin(Carbo) or Cisplatin (Carbo)+ 5-FU.
Title: Phase III randomized study to compare the early chemotherapy with Docetaxel plus androgen ablation to androgen ablation alone in prostate cancer patients with extensive disease.
This Phase III study is for patients with pancreatic cancer who have had surgical resection. Patients will be randomized to receive adjuvant therapy, Gemcitabine or 5-FU chemoradiation with or without immunotherapy with HyperAcute Pancreatic Cancer Vaccine.
Title: Phase III blinded study of immediate post-TURBT instillation of Gemcitabine versus Saline in patients with newly diagnosed or occasionally recurring grade I/II superficial bladder cancer.
This Phase III study compares the recurrence-free survival as well as overall survival of patients with renal cell carcinoma receiving everolimus or placebo after full surgical resection and who have no residual or metastatic disease.
Yondelis is an anticancer agent discovered from the sea squirt, Ecteinascidia turbinate that is now produced synthetically. It binds to DNA resulting in DNA damage within cancer cells and leading to their death. In this randomized Phase III study Yondelis or Decarbazine is given to patients with advanced liposarcoma or leiomyosarcoma who have previously received the standard chemotherapies anthracycline and ifosfamide.
